Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer Clinical Trial

Official title:

A Study of CLDN18.2 Chimeric Antigen Receptor T Cells in the Treatment of Advanced Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04966143
• Other study ID #: LY011C1001
• Status: Recruiting
• Phase: Early Phase 1
• Start date: August 1, 2021
• Est. completion date: August 1, 2024

Study information

• Verified date: July 2021
• Source: Shanghai Longyao Biotechnology Inc., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CLDN 18.2 chimeric antigen receptor T cells Clinical research plan for the treatment of recurrent or refractory pancreatic cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: August 1, 2024
• Est. primary completion date: August 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• They were 18 to 70 years old, male or female;

• Definitive diagnosis is recurrent or refractory pancreatic cancer;

• Claudin 18.2 IHC staining was positive in tumor tissues;

• Life expectancy > 12 weeks;

• According to RECIST 1.1, there was at least one measurable tumor target;

• ECoG scores at screening, 24 hours before puncture and baseline (before treatment) were 0-1;

• Adequate organ function;

• Women of childbearing age with negative pregnancy test or male subjects must take effective and reliable contraceptive methods until 30 days after the end of treatment;

• Have enough understanding ability to voluntarily sign informed consent to participate in clinical research.

Exclusion Criteria:

• Pregnant or lactating women;

• HIV, syphilis spirochete or HCV serological positive;

• Any uncontrollable active infection, including but not limited to active tuberculosis, HBV infection (HBsAg positive, HBcAb positive, HBV DNA positive);

• The subjects were judged as clinically significant thyroid dysfunction by the investigators (serum thyroid hormone determination TT4, TT3, FT3, FT4, serum thyroid stimulating hormone TSH) and were not suitable to participate in this study;

• The side effects of the patients were not recovered to CTCAE = 1;

• Subjects who are currently using steroids all over the body within 7 days before the pregnancy is taken out; Inhaled steroids are not excluded in the near future or in the near future;

• Previous allergies to immunotherapy and related drugs, severe allergies or allergies;

• T cells (including car-t, tcr-t) that have been modified by chimeric antigen receptor have been reported.

• The subjects had untreated or symptomatic brain metastasis;

• The subjects had heart disease which needed treatment or after treatment, hypertension was out of control (blood pressure > 160 mmHg / 100 mmHg);

• Subjects with or waiting for organ transplantation history;

• No other serious disease may limit subjects' participation in this trial

• The researchers assessed that subjects were unable or unwilling to comply with the requirements of the study program.

• It has abnormal signs of central nervous system diseases or abnormal results of nervous system detection, which has clinical significance;

• Subjects currently or had other malignant tumors that could not be cured within 3 years, except for in situ cervical or skin basal cell carcinoma.

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Biological:
• LY011
Targeting CLDN 18.2 Car-T injection

Locations

Country	Name	City	State
China	The Affiliated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Longyao Biotechnology Inc., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response rate(ORR)	the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria	1month
Secondary	Progression free survival(PFS)	Survival witouth observed progression at 2 years	1 years
Secondary	Disease Control Rate(DCR)	DCR (CR+PR+SD) by RECIST v1.1	1 years
Secondary	Duration of Response (DOR)	DOR was defined as the time from the first documented a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: =30% decrease in the sum of diameters of target lesions) to progressive disease (PD was defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of =5 mm.	1 years
Secondary	Overal survival (OS)	survival at 5 years	5 years
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	AEs according to CTCAE v 5.0.	1 year